Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 in “NEO-CYT” trial in High-Risk, Surgically Resectable Neoadjuvant Stage III Melanoma
Professor Paolo A. Ascierto, Lead Principal Investigator of NEO-CYT, commented: “Neoadjuvant therapy has taught us that timing of immunotherapy matters. Treating patients undergoing curative surgery while the tumor is still present can generate deeper and more durable immune responses. Advancing into the neoadjuvant setting represents a logical next-step in clinical development of any promising immunotherapy by treating earlier-stage, high-risk patients. Importantly, NEO-CYT is designed to evaluate combinations of MDNA11 with two major immunotherapies, nivolumab with or without ipilimumab. NEO‑CYT will test whether adding a next-generation IL-2 superkine, MDNA11, to proven checkpoint combinations in resectable, high-risk melanoma can improve pathologic responses with the potential to improve curative benefit after surgery.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month